SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Advanced NSCLCOctober 2, 2026

Sutetinib produced responses in 71% of patients with uncommon EGFR mutations in a phase IIb trial

A multicentre, open-label, single-arm phase IIb trial of sutetinib in advanced non-small cell lung cancer (NSCLC) with uncommon EGFR mutations met its primary endpoint, with an objective response rate of 70.8% confirmed by an independent review committee. Fengying Wu and colleagues reported the results in the Journal of Thoracic Oncology.
Share

In brief

  • Sutetinib, an irreversible EGFR tyrosine kinase inhibitor, produced an objective response rate of 70.8% by independent review in 96 efficacy-evaluable patients with advanced NSCLC carrying uncommon EGFR mutations.
  • Median progression-free survival was 13.7 months and median duration of response 12.0 months after a median follow-up of 16.6 months; median overall survival was not reached.
  • The response rate was numerically higher with compound than with solitary uncommon mutations (84.4% vs 64.1%), with median progression-free survival of 13.8 and 11.0 months.
  • Grade 3 or higher treatment-related adverse events occurred in 42.4% of the 99 treated patients, most often diarrhoea (28.3%), and 4.0% stopped treatment because of them.
  • The phase IIb trial had a single arm, so its results cannot be set directly against another EGFR inhibitor in this population.

Study at a glance

  • Trial: Phase IIb, multicentre, open-label, single-arm (NCT05168566)
  • Population: Adults with locally advanced or metastatic NSCLC carrying EGFR G719X, S768I, L861Q or predefined compound mutations, with no prior EGFR TKI
  • Enrolment: 99 patients between 9 December 2021 and 5 May 2024; 96 evaluable for efficacy
  • Treatment: Sutetinib 80 mg orally once daily in 28-day cycles, until radiographic progression or unacceptable toxicity
  • Primary endpoint: Objective response rate by independent review committee, 70.8%
  • Survival: Median PFS 13.7 months; median OS not reached; median follow-up 16.6 months at the October 2024 data cut-off
  • Compound vs solitary mutations: ORR 84.4% vs 64.1%; median PFS 13.8 vs 11.0 months
  • Safety: Grade 3 or higher TRAEs 42.4%; dose reduction 34.3%; discontinuation 4.0%; no treatment-related deaths
  • Not reported: In the abstract, response rate for each individual mutation, activity in brain metastases, median time to response, subgroup sizes

A 70.8% response rate on independent review

The independent review committee confirmed responses in 70.8% of the 96 efficacy-evaluable patients (95% confidence interval [CI], 60.7–79.7), and the disease control rate was 90.6% (95% CI, 82.9–95.6).

Responses lasted a median of 12.0 months (95% CI, 9.3–15.7). Median progression-free survival was 13.7 months (95% CI, 10.9–16.4). Median overall survival had not been reached at the October 2024 cut-off, and the lower bound of its confidence interval was 22.2 months.

The efficacy analysis took in every patient who received at least one dose and could be evaluated, which left three of the 99 enrolled patients outside it. The safety analysis covered all 99.

Higher response with compound than with single uncommon mutations

Patients with predefined compound mutations had an objective response rate of 84.4%, against 64.1% in those with a solitary uncommon mutation, and a median progression-free survival of 13.8 against 11.0 months. The authors describe the difference as numerical, and the abstract gives no statistical comparison between the two groups.

Uncommon mutations account for about 10% of EGFR-altered NSCLC, and their sensitivity to EGFR inhibitors differs from one alteration to the next. The authors note that prospective evidence to guide first-line therapy in this group has been limited. Afatinib’s US label was extended to G719X, S768I and L861Q in 2018 on a post hoc analysis of its earlier trials, so a prospective trial built around these mutations adds a different kind of evidence.

Diarrhoea led the grade 3 or higher adverse events

Almost every treated patient, 96 of 99 (97.0%), had a treatment-related adverse event of some grade, and 42 (42.4%) had one of grade 3 or higher.

Diarrhoea was the most common severe event, at 28.3% (28 of 99), followed by hypokalaemia at 8.1% and increased gamma-glutamyl transferase at 5.1%. Treatment-related adverse events led to a dose reduction in 34.3% of patients and to discontinuation in 4.0%. No treatment-related deaths occurred.

Dose reductions (34 patients) were more than eight times as common as discontinuations (4 patients), which suggests that the toxicity at 80 mg once daily was more often handled by lowering the dose than by stopping treatment.

“Sutetinib met the prespecified primary endpoint and demonstrated clinically meaningful antitumor activity with a manageable safety profile in advanced NSCLC harboring uncommon EGFR mutations (G719X, S768I, and L861Q).”Wu et al., Journal of Thoracic Oncology (2026)

No comparator arm and 16.6 months of median follow-up

With no control group, the 70.8% response rate and 13.7-month median progression-free survival cannot be compared directly with afatinib, osimertinib or chemotherapy in the same population.

The mutation mix matters for the same reason. Because compound mutations responded more often, the overall figures depend on what share of patients carried them, and a trial with a different mix could report a different overall rate.

Overall survival will need longer follow-up, since fewer than half of the patients had died by the data cut-off.

Sources

  1. Journal of Thoracic Oncology. Sutetinib for Patients with Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Multicenter, Open-Label, Phase IIb Trial (2026-08-01). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Xiuning Le.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW
Advanced NSCLCImmunotherapies

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck
Sep 26 2025
ILCS 2025
Advanced NSCLC

Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond

} 32 min

A. Curioni-Fontecedro
Sep 26 2025
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

A. Curioni-Fontecedro
Sep 26 2025
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

Unlocking New Potentials in EGFR-Mutant NSCLC

} 30 min

A. Passaro
Sep 26 2025
ILCS 2025
Targeted Therapies

DEBATE: Which Is the Better Choice in EGFR+ Advanced NSCLC?

} 31 min

T. Newsom-DavisX. Le
Sep 26 2025
ILCS 2025
Targeted Therapies

Actionable Genomic Alterations – Including HER2 and MET

} 26 min

S. Saw
Sep 26 2025
ILCS 2025
Targeted Therapies

Targeting EGFR and ALK in NSCLC

} 26 min

T. John
Sep 26 2025
ILCS 2025
Advanced NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCTargeted Therapies

Targeted Therapies in NSCLC

} 1h 30 min

O. GautschiJ. NaidooN. Girard
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Charles Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

SCLC transformation in 5 of 11 patients given first-line osimertinib with platinum and etoposide

C. Rudin
Nov 14 2026
RESEARCH
Advanced NSCLCBiomarkersADCs

Membrane share of TROP2 identified longer PFS on Dato-DXd in nonsquamous NSCLC

J. SandsM. PérolN. Girard
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nov 04 2026
RESEARCH
Advanced NSCLCImmunotherapies

Local ablative therapy alone after durvalumab was followed by an mOS of 18.7 months in oligoprogressive NSCLC

A. FilippiL. Hendriks
Nov 01 2026
RESEARCH
Advanced NSCLCBiomarkersTargeted Therapies

Secondary ALK resistance mutations found in 8% of ALK-positive NSCLC samples on genomic profiling

P. Hofman
Oct 31 2026
RESEARCH
Advanced NSCLCTargeted Therapies

VTE reporting in fusion-positive NSCLC trials is fragmented across publications and registries

A. Cortellini
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
Advanced NSCLCImmunotherapies

Adding chemotherapy to pembrolizumab lengthened PFS in PD-L1-high advanced NSCLC in PERSEE

M. Pérol
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 22 2026
RESEARCH
Advanced NSCLC

TP53 Y220C occurs in 0.7% of NSCLC and more often in EGFR-mutant tumours, in an ETOP study of 28,244 patients

R. StahelL. BubendorfL. HendriksS. PetersS. Finn
Oct 21 2026
SPONSORED
Advanced NSCLCImmunotherapies

The “tail of the curve” is real: long-term survival in PD-L1–negative metastatic NSCLC

A. Curioni-Fontecedro
Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 19 2026
RESEARCH
Advanced NSCLCImmunotherapies

Nivolumab plus ipilimumab in 545 Japanese patients with metastatic NSCLC: the LIGHT-NING 2.5-year update

H. Horinouchi
Oct 18 2026
RESEARCH
Advanced NSCLCTargeted Therapies

First-line firmonertinib produced responses in 68% of patients with EGFR PACC-mutant NSCLC at 240 mg

X. LeD. PlanchardM. Pérol
Oct 16 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Platinum-pemetrexed after selective RET inhibitor failure gave a median real-world PFS of 6.1 months

A. CallesJ. RemonA. CortelliniD. PlanchardB. Ricciuti
Oct 16 2026
RESEARCH
Advanced NSCLC

Fixation protocol determined immunocytochemistry performance on lung cancer cytology slides in an IASLC study

L. Bubendorf
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Advanced NSCLCTargeted Therapies

Durable responders to immunotherapy for NSCLC or melanoma mostly reported good health, but frequent fatigue

N. Girard